Chongqing Study on Primary Aldosteronism and Essential Hypertension with Long-Term Follow-Up of Cardiovascular and Kidney Outcomes

What this Trial Is About

Researchers are conducting a series of clinical studies on primary aldosteronism PA and essential hypertension to create a large group of patients for long-term follow-up. They aim to study cardiovascular events, kidney outcomes, and other health effects over up to 15 years. The study also involves collecting samples like blood, urine, and adrenal tissue to build databases of genetic, metabolic, and protein information to better understand PA and related organ damage. Participants include people with PA and essential hypertension who are screened and classified following guidelines. There is no intervention or treatment given as part of the study. Instead, the research focuses on observing and analyzing the participants over time, including those diagnosed with PA and those without it. During the study, participants will be followed for 1 to 15 years with assessments of cardiovascular events, kidney function using estimated glomerular filtration rate eGFR, the occurrence of atrial fibrillation, changes in heart structure, artery thickness, and quality of life. Researchers will collect and analyze biological samples and health data to explore risk factors, diagnostic methods, and biomarkers. The total participation time depends on individual follow-up within the study period ending in 2028.

Chongqing Primary Aldosteronism Study